Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in CTEPH
NCT04271475Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan with Placebo (2 arms). Primary endpoint: Change From Baseline in 6-minute Walk Distance at 28 weeks. Started Jul 2020; status: terminated.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT04271475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271475.